SurvivorNet on MSN
New lung cancer drug, Ivonescimab, showed promising results in major HARMONi-6 trial, but US patients will need to wait for HARMONi-3 update
A new drug called ivonescimab just beat standard immunotherapy in a major lung cancer trial: patients lived nearly four ...
Scientists have identified proteins that could signal increased lung cancer risk, as well as a drug that could reduce the ...
Researchers at the University of Cincinnati College of Medicine have found that patients who continue to smoke ahead of lung ...
The Lung Cancer Research Foundation (LCRF), in collaboration with AstraZeneca, today announced that two research awards ...
Presentations at the 51st ONS Congress explained how oncology nurses can help patients navigate the often-bewildering terrain ...
Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung ...
The Lung Cancer Research Foundation announced today that a new, two-year, $300,000 research award focused on accelerating ...
SurvivorNet on MSN
A new type of immunotherapy drug showed striking results in hard-to-treat lung cancer, but more data is needed for US patients
A large clinical trial in China (HARMONi-6) found that a new immunotherapy drug, ivonescimab, may help patients with advanced ...
Abenacianine, a fluorescent imaging agent, received FDA fast track status for enhancing tumor visualization during lung cancer surgery, showing safety and efficacy in phase 2 trials. Alecensa ...
The FLAURA2 trial showed that combining Tagrisso with chemotherapy improved survival in EGFR-mutated NSCLC, especially in patients with liver metastases and TP53 alterations. Addressing emotional and ...
Lung cancer poses a potential smoke screen for today’s pulmonologists. Overall, incidence rates continue to decline in the US as other cancers are on the rise, yet a growing number of patients are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results